Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Baton Rouge, Louisiana 70808


Purpose:

This is a research study of an investigational drug, APD356, a novel, selective 5-HT2c receptor agonist, in clinical development as a potential treatment for obesity. The purpose of this study is to obtain preliminary assessment of the safety and efficacy of APD356, when administered daily for 28 days, in obese subjects who are otherwise healthy.


Study summary:

This is a double-blind, placebo-controlled, randomized, parallel group study. Three different doses of APD356 or placebo will be administered daily for 28 days, to uncomplicated obese, male and nonpregnant, nonlactating, female volunteers, aged 18 to 65 years. Approximately 400 subjects will be enrolled.


Criteria:

- Healthy male or nonpregnant, nonlactating females aged between 18 and 65 years (inclusive) - Body Mass Index (BMI) of 30-45 Kg/m^2. - Non-smoker - No concomitant medications - No past treatment with drugs associated with the development of pulmonary hypertension or cardiac valvular insufficiency


NCT ID:

NCT00104507


Primary Contact:

Study Chair
William R Shanahan, Jr, MD
Arena Pharmaceuticals


Backup Contact:

N/A


Location Contact:

Baton Rouge, Louisiana 70808
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: December 10, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.